|
|
12481 High Bluff Drive, Suite 200
San Diego, CA 92130 USA
phone:858-436-1400
fax:858-436-1401
|
|
| Symbol |
CADX |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.cadencepharm.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Pharmaceuticals utilized primarily in the hospital setting. |
|
| Management |
| Theodore R. Schroeder, President, Chief Executive Officer and Director; James B. Breitmeyer M.D., Ph.D., Executive Vice President, Development and Chief Medical Officer; Hazel M. Aker J.D., Senior Vice President, General Counsel and Secretary; William S. Craig Ph.D., Senior Vice President, Pharmaceutical Development and Manufacturing; William R. LaRue, Senior Vice President, Chief Financial Officer, Treasurer and Assistant Secretary; Malcolm Lloyd-Smith,
Senior Vice President, Regulatory Affairs and Quality Assurance; David A. Socks, Senior Vice President, Corporate Development and Strategy; Catherine J. Hardalo M.D., Vice President, Clinical Development, Anti-Infectives; Mike A. Royal M.D., M.B.A., J.D, Vice President, Clinical Development, Analgesics; Diane K. Sheehan, Vice President, Human Resources |
| |
|
|
|
|
|
|
|
| Keywords |
| woundwound, woundcare |
|
|
|
| Description |
|
Cadence Pharmaceuticals is focused on the development and commercialization of pharmaceuticals utilized primarily in the hospital setting. |
|
| Products / Services |
In August 2004, Cadence licensed the North American and European rights to its first product, CPI-226 (omiganan 1% aqueous gel) for the prevention of wound, burn, and device-related infections from Migenix, Inc. Initial development is focused on the prevention of central venous catheter (CVC) related infections, particularly amongst hospitalized and hemodialysis patients.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
